Chemical Namenintedanib
Dosage FormCapsule (oral; 150mg and 100mg)
Drug ClassKinase inhibitors
CompanyBoehringer Ingelheim Pharmaceuticals
Approval Year2014


  • For the treatment of idiopathic pulmonary fibrosis (IPF).
  • For the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
  • For the slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ofev (nintedanib) Prescribing Information 2014Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT